Venous access port with molded and/or radiopaque indicia

Information

  • Patent Grant
  • 8852160
  • Patent Number
    8,852,160
  • Date Filed
    Monday, July 16, 2012
    11 years ago
  • Date Issued
    Tuesday, October 7, 2014
    9 years ago
Abstract
A venous access port assembly having a housing base, a flange, and a septum. The housing base defines an interior reservoir. The flange includes integrally molded X-ray discernable indicia identifying that the assembly is rated for power injection. The X-ray discernable indicia may extend through a height of the flange from a top surface to a bottom surface of the flange. According to one aspect, the flange may be formed from X-ray discernable material, and the X-ray discernable indicia may be formed from the X-ray discernable material of the flange, or they may be formed by voids in the X-ray discernable material. According to another aspect, the flange may be formed from a radiotransparent or radiolucent material and applied with a radiopaque agent, and the X-ray discernable indicia may be one or more voids in the radiopaque agent or may be portions of the flange applied with the radiopaque agent.
Description
FIELD OF THE INVENTION

This invention relates generally to medical devices, and more particularly to venous access ports having integrally molded and/or radiopaque indicia.


BACKGROUND OF THE INVENTION

Venous access ports for the infusion and/or withdrawal of fluids from a patient are well-known, secured to the proximal end of an implanted catheter. These ports are typically used for drug infusion or for withdrawal of small amounts of blood, where large flows of fluid are not required. The ports are assemblies of a needle-impenetrable housing with a discharge port in fluid communication with a catheter and a reservoir within the port housing, and provide a subcutaneous self-sealing septum that defines an access site for multiple needle sticks through the covering skin tissue of the patient, through the septum, and into the reservoir, without the need to continuously search for new access sites. Examples of such ports are disclosed, for example, in U.S. Pat. Nos. 4,704,103; 4,762,517; 4,778,452; 5,185,003; 5,213,574; and 5,637,102.


It is desired to provide a venous access port assembly that provides a medical practitioner with the capability to discern an important property of the port assembly after the port assembly has been implanted into a patient.


BRIEF SUMMARY OF THE INVENTION

The present invention is directed to an implantable venous access port having a marking visible by X-ray examination, providing identification on the X-ray of characteristics of the implanted access port. These characteristics might otherwise be unknown once the port is implanted under the skin of the patient. Considering that X-ray examination is normal practice prior to medical access of the port, an X-ray examination that also identifies important characteristics of an implanted port is beneficial to the practitioner.


Accordingly, one aspect of the present invention is the incorporation of a molded marking into or onto the venous access port, or the addition of radiopaque indicia onto the access port, and/or the addition of radiopaque indicia onto a molded marking integrated into the access port, all of which would be discernable under X-ray examination to provide information concerning a characteristic or attribute of the venous access port, so that a practitioner, subsequent to implantation of the access port under the skin of a patient, can determine that characteristic or attribute of the port by X-ray examination.


One such characteristic could be power injectable capability; that is, an indication that the venous access port is rated for the power injection of contrast fluid. Power injection capability can be indicated with the letters “CT,” for “computed tomography,” or “contrast enhanced computed tomography.” “CT” would indicate the access port's capability to withstand high pressures used during injection of contrast fluid into a patient, and the letters “CT” would be understood in medical practice to indicate that the port is suitable for the high pressure injection of contrast fluid. Naturally, any characteristic or attribute of the venous access port could be indicated, and any choice of letters or symbols could be employed.


In one embodiment, an access port of the present invention includes a housing and a septum, providing an interior reservoir and a passageway extending from the reservoir through a stem of a discharge port to establish fluid communication with a proximal end of a catheter lumen to which the port assembly is secured prior to placement of the assembly into a patient. The port may optionally have more than one reservoir and associated septum. The housing could include molded therein the letters “CT.” If the housing is made of a plastic material, such as a silicone elastomer, the letters “CT” (or the entire housing) could be loaded with a radiopaque agent, allowing the letters “CT” (or the entire housing) to be seen by X-ray examination. If the housing comprises a metal material, or if the portion of the housing including the letters “CT” is made of a metal material, the letters would naturally be visible by X-ray examination.





BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated herein and constitute part of this specification, illustrate the presently preferred embodiments of the invention, and, together with the general description given above and the detailed description given below, serve to explain the features of the invention. In the drawings:



FIG. 1 is an isometric view of one embodiment of a venous access port of the present invention;



FIG. 2 is a plan view of the port of FIG. 1;



FIGS. 3 and 4 are cross-sectional views of the port of FIGS. 1 and 2 taken along lines 3-3 and lines 4-4 of FIG. 2, respectively;



FIG. 5 is an isometric view of a needle-impenetrable housing base of the venous access port of FIG. 1;



FIGS. 6 and 7 are transverse cross-sectional and longitudinal cross-sectional views of the housing base of FIG. 5;



FIG. 8 is an isometric view from below of one embodiment of the housing base of FIG. 5, showing radiopaque indicia applied on the housing base bottom surface;



FIGS. 9 and 10 are bottom and top views of the housing base of FIG. 8 having radiopaque indicia thereon, with the top view (FIG. 10) being analogous to a X-ray view of the venous access port seen by a radiologist, with indicia visible by X-ray shown by dashed lines in FIG. 10;



FIG. 11 illustrates top views of two alternative embodiments of the needle-impenetrable housing base of the venous access port of FIG. 1, showing integrally molded “CT” markings;



FIG. 12 illustrates an isometric view of one of the FIG. 11 embodiments of the needle-impenetrable housing base of the venous access port of FIG. 1, featuring an integrally molded “CT” marking where the letters “CT” are formed of housing material; and



FIG. 13 illustrates an isometric view of the other of the FIG. 11 embodiments of the needle-impenetrable housing base of the venous access port of FIG. 1, featuring an integrally molded “CT” marking where the letters “CT” comprise voids in the housing material, as if cut or punched out of the housing material.





DETAILED DESCRIPTION OF THE INVENTION

Certain terminology is used herein for convenience only and is not to be taken as a limitation on the present invention. The terms “distal” and “proximal” refer, respectively, to directions closer to and away from the insertion tip of a catheter in an implantable catheter assembly. The terminology includes the words specifically mentioned, derivatives thereof, and words of similar import. The embodiments illustrated below are not intended to be exhaustive or to limit the invention to the precise form disclosed. These embodiments are chosen and described to best explain the principle of the invention and its application and practical use and to enable others skilled in the art to best utilize the invention.


Venous access port assembly 10 of FIGS. 1 to 4 includes a housing 12 and a septum 14, with a discharge port 16 extending from a distal end 18 of the port assembly 10 to be attached securely and sealingly to the proximal end of a catheter (not shown). A passageway 20 extends from the interior reservoir 22 to the distal tip opening 24 of discharge port 16. A recess 26 is seen to be provided along both sides of discharge port 16, facilitating insertion of the discharge port 16 into the catheter lumen and providing a clearance for a locking sleeve or clamp (not shown) utilized to compress the catheter lumen wall against the exterior surface of the discharge port 16 for assured sealed connection of the catheter with the port assembly 10.


With reference now to FIGS. 3 to 7, the interior of the port assembly 10 is shown to provide an interior reservoir 22. Housing 12 is shown to include a housing base 28 of needle-impenetrable material that includes a well 30 having a bottom floor 32 and side walls 34 that define the interior reservoir 22 beneath septum 14. Bottom floor 32 may be convex or elevated (not shown) toward the center of the reservoir, if desired. Housing base 28 includes a base flange 36 extending radially outwardly from the bottom of well 30, and base flange 36 includes openings 38, 40 that serve to enable suturing to the patient upon placement of the venous access port and the attached catheter into the patient.


As shown in FIGS. 3 and 4, a skirt 42 is overmolded about housing base 28 and may be of silicone elastomer. It is seen that skirt 42 encapsulates the outer surfaces of the bottom wall 44 and the bottom portion of the side walls 46 of housing base 28, and is shown to fill in the suture holes 38, 40; but since the material is silicone elastomer, suturing is possible since the suturing needle can easily be inserted through the material of skirt 42 and through the suture holes, and thereafter the filled openings provide minimal opportunity for ingrowth of patient tissue into the openings.


Also seen in FIGS. 1 to 4 is cap 48, which secures to housing base 28 to in turn secure septum 14 in position in the port assembly 10. Preferably, skirt 42 is insert molded onto base flange 36 of housing base 28 after cap 48 is secured to the upper portion of housing base 28 to secure the septum in position. It is seen in FIGS. 4 and 7 that discharge port 16 is integral with housing base 28 as is preferable. Discharge port 16 is shown to have a pair of annular ridges 50 that facilitate with the mechanical connection of the catheter proximal end with the port assembly 10. Housing base 28 includes a septum seat 52 extending into the top of well 30, into which a flange of the septum will be seated, preferably under radially inward compression. Housing base 28 has a bottom outer surface 54.


Radiopaque markings 60 of the present invention are shown in FIGS. 8 to 10. A larger outer circle 62 is seen provided on the outermost periphery of bottom base surface 54, and a smaller inner circle 64 is seen provided within the area circumscribed by the suture openings 38 and holes 40 through base flange 36. Adjacent to discharge port 16, a recess 56 is provided in the skirt of the housing base to provide a clearance for use of a connection sleeve that will be used to secure the catheter (not shown), and outer circle 62 is shown to have a gap 66 at the recess. Outer and inner circles or rings 62, 64 circumscribe radiopaque indicia 70.


Radiopaque indicia 70 are provided on bottom outer surface 54 within the region directly beneath the reservoir and septum. In the example shown, indicia 70 comprise the letters “CT” (FIG. 10) representing the term “computed tomography.” The meaning of this particular example of indicia is that the venous access port assembly 10 is rated for high pressure injection such as is necessary for infusion into the patient of contrast medium that is used in computed tomography. Other indicia may of course be used that indicate some other attribute or characteristic of the venous access port assembly. The radiopaque markings and indicia would appear on an X-ray of the patient, and the indicia are provided in a mirror-image orientation on the bottom outer surface of the housing base (FIGS. 7 and 8) so that the indicia would appear as “CT” when the X-ray is viewed (FIG. 9), easily discerned by the radiologist or technologist. Centering of the indicia within the region (identified as “30, 22” in FIG. 10) directly beneath the reservoir and septum minimizes any obscuring by the structure of the venous access port assembly, and the indicia may also be easily discernable should the port assembly be at an angle from the horizontal plane of the X-ray; the outer and inner circles 62, 64 would appear oval or elliptical should the port assembly be at such an angle. Gap 66 in outer circle 62 would also appear and would indicate the location of the discharge port stem 16.


The radiopaque markings may constitute marking fluid that is embossed or imprinted or otherwise applied onto the surface of the housing base 28, such as black radiopaque ink Part No. C11002 Rev A formulated by CI Medical, Inc., 15 Commerce Way, Norton, Mass. 02766, from Marabu Tampapur TPU 910 clear with tungsten added, available from Marabuwerke GmbH & Co. KG of Stuttgart, Germany, and may be applied on plasma-treated surfaces. At least the housing base 28, the septum 14 and the skirt 42 are of radiotransparent or radiolucent material as is well known in implanted medical devices, and the housing base may be molded of polysulfone resin.


The radiopaque markings may alternatively applied to the inwardly facing surface of the bottom wall of the housing base, or may constitute foil or film (such as a decal) of radiopaque material embedded within the housing base, these alternatives not being shown in the drawings.



FIG. 11 illustrates top views of two alternative embodiments 72, 74 of the needle-impenetrable housing base 28 of the venous access port 10 of the present invention. Each of the alternative embodiments 72, 74 shows “CT” markings integrally formed in the base flange 36 of the housing base 28. The first alternative embodiment 72, an isometric view of which is illustrated in FIG. 12, features integrally molded “CT” markings within the suture openings 38, where the letters “CT” are formed of the base flange 36 material. The second alternative embodiment 74, an isometric view of which is illustrated in FIG. 13, features integrally molded “CT” markings alongside the suture openings 38, 40, where the markings are voids in the base flange 36 material, as if cut or punched out of the base flange 36 material. Naturally, the markings could be configured elsewhere within or about the housing base 28, or within a peripheral portion of another component of the venous access port 10.


If the housing base 28 is made of a plastic material, such as a silicone elastomer or polysulfone resin, the letters “CT,” or the base flange 36, or the entire housing base 28, could be applied with a radiopaque agent or fluid, allowing the applied area to be visible by X-ray examination. If the housing base 28 is comprised of a metal material, or if the base flange 36, or a portion thereof, is comprised of metal (particularly the letters “CT”), those portions would naturally be visible by X-ray examination without application of the radiopaque agent.


It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the spirit and scope of the present invention as defined by the appended claims.

Claims
  • 1. A venous access port assembly for implantation into a patient, comprising: a housing comprising: a base defining at least one reservoir; and a flange adjacent to the at least one reservoir, the flange comprising an X-ray discernable material, a top surface, a bottom surface, and one or more voids extending through the X-ray discernable material of the flange from the top surface of the flange to the bottom surface of the flange, wherein the one or more voids are X-ray discernable indicia configured to indicate, under X-ray examination, that the assembly is rated for power injection; and a needle-penetrable septum communicating with the housing.
  • 2. The assembly of claim 1, wherein at least a portion of the X-ray discernable material is disposed within the one or more voids.
  • 3. The assembly of claim 1, wherein the flange extends outwardly from the at least one reservoir.
  • 4. The assembly of claim 1, wherein the flange extends outwardly from the base about a perimeter of the at least one reservoir.
  • 5. The assembly of claim 1, wherein the housing further comprises a skirt overmolded about at least a portion of the base.
  • 6. The assembly of claim 5, wherein the skirt is further overmolded about the flange.
  • 7. The assembly of claim 5, wherein the skirt comprises a radiotransparent or radiolucent material.
  • 8. The assembly of claim 1, wherein the X-ray discernable indicia further indicate, under X-ray examination, that the assembly is adapted to withstand high pressures used for injection of contrast fluid.
  • 9. A venous access port assembly for implantation into a patient, comprising: a housing comprising: a housing base defining at least one reservoir; and a flange adjacent to the at least one reservoir, the flange comprising an X-ray discernable material, a top surface, a bottom surface, and one or more voids extending through the X-ray discernable material of the flange from the top surface of the flange to the bottom surface of the flange, wherein the one or more voids are X-ray discernable indicia configured to indicate, under X-ray examination, that the assembly is rated for power injection; and a needle-penetrable septum secured to the housing.
  • 10. The venous access port assembly of claim 9, wherein at least a portion of the X-ray discernable indicia are material is disposed within the one or more voids.
  • 11. The venous access port assembly of claim 9, wherein the flange extends outwardly from the at least one reservoir.
  • 12. The venous access port assembly of claim 9, wherein the flange extends outwardly from the housing base about a perimeter of the at least one reservoir.
  • 13. The venous access port assembly of claim 9, wherein the housing further comprises a radiotransparent or radiolucent skirt overmolded about at least a portion of the housing base.
  • 14. The venous access port assembly of claim 13, wherein the radiotransparent or radiolucent skirt is further overmolded about the flange.
  • 15. The venous access port assembly of claim 9, wherein the X-ray discernable indicia further indicate, under X-ray examination, that the assembly is adapted to withstand high pressures used for injection of contrast fluid.
  • 16. A venous access port assembly for implantation into a patient, comprising: a housing comprising: a housing base comprising a well comprising a bottom floor and side walls, the bottom floor and side walls defining at least one reservoir; and a flange adjacent to the at least one reservoir, the flange comprising an X-ray discernable material, a top surface, a bottom surface, and one or more voids extending through the X-ray discernable material of the flange from the top surface of the flange to the bottom surface of the flange, wherein the one or more voids are X-ray discernable indicia configured to indicate, under X-ray examination, that the assembly is rated for power injection; a needle-penetrable septum; and a cap securing the needle-penetrable septum to the housing.
  • 17. The venous access port assembly of claim 16, wherein at least a portion of the X-ray discernable material is disposed within the one or more voids.
  • 18. The venous access port assembly of claim 16, wherein the flange extends outwardly from the well.
  • 19. The venous access port assembly of claim 16, wherein the flange extends outwardly from the housing base about a perimeter of the at least one reservoir.
  • 20. The venous access port assembly of claim 16, wherein the housing further comprises a radiotransparent or radiolucent skirt overmolded about at least a portion of the housing base.
  • 21. The venous access port assembly of claim 20, wherein the radiotransparent or radiolucent skirt is further overmolded about the flange.
  • 22. The venous access port assembly of claim 16, wherein the X-ray discernable indicia further indicate, under X-ray examination, that the assembly is adapted to withstand high pressures used for injection of contrast fluid.
RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 12/143,377, filed Jun. 20, 2008 and entitled “Venous Access Port With Molded and/or Radiopaque Indicia,” now U.S. Pat. No. 8,257,325, which claims the benefit of U.S. Provisional Application Ser. No. 60/936,491, filed Jun. 20, 2007 and entitled “Venous Access Port With Molded and/or Radiopaque Indicia,” which applications are incorporated herein by reference.

US Referenced Citations (526)
Number Name Date Kind
574387 Buckler Jan 1897 A
611357 Dembinski Sep 1898 A
966696 Merrill Aug 1910 A
1713267 Crowley May 1929 A
2029553 Bartschi et al. Feb 1936 A
2433480 Rendich Dec 1947 A
2891689 Gould Jun 1959 A
D198453 Weichselbaum Jun 1964 S
3293663 Cronin Dec 1966 A
3341417 Sinaiko Sep 1967 A
3518428 Ring Jun 1970 A
3529633 Vaillancourt Sep 1970 A
3643358 Morderosian Feb 1972 A
3829904 Ling et al. Aug 1974 A
3831583 Edmunds, Jr. et al. Aug 1974 A
3840009 Michaels et al. Oct 1974 A
3891997 Herbert Jul 1975 A
3915162 Miller Oct 1975 A
3919724 Sanders et al. Nov 1975 A
3922726 Trentani et al. Dec 1975 A
3951147 Tucker et al. Apr 1976 A
4027391 Samis et al. Jun 1977 A
4035653 Karasko Jul 1977 A
4121108 Manor Oct 1978 A
4123806 Amstutz et al. Nov 1978 A
4168586 Samis Sep 1979 A
4190040 Schulte Feb 1980 A
4190057 Hill et al. Feb 1980 A
4194122 Mitchell et al. Mar 1980 A
4202349 Jones May 1980 A
4222374 Sampson et al. Sep 1980 A
4233964 Jefferts et al. Nov 1980 A
4274006 Caine Jun 1981 A
4349498 Ellis et al. Sep 1982 A
4361153 Slocum et al. Nov 1982 A
4405305 Stephen et al. Sep 1983 A
4406567 Samis et al. Sep 1983 A
4425119 Berglund Jan 1984 A
4445896 Gianturco May 1984 A
4450592 Niederer et al. May 1984 A
4450985 Beard May 1984 A
4456011 Warnecke et al. Jun 1984 A
4469483 Becker et al. Sep 1984 A
4494545 Slocum et al. Jan 1985 A
4506676 Duska Mar 1985 A
4529635 Sheldon Jul 1985 A
4543088 Bootman et al. Sep 1985 A
4549879 Groshong et al. Oct 1985 A
4559046 Groshong et al. Dec 1985 A
4560375 Schulte et al. Dec 1985 A
4571749 Fischell Feb 1986 A
4576595 Aas et al. Mar 1986 A
4587954 Haber May 1986 A
4612877 Hayes et al. Sep 1986 A
4626244 Reinicke Dec 1986 A
4627844 Schmitt Dec 1986 A
4634427 Hannula et al. Jan 1987 A
4636194 Schulte et al. Jan 1987 A
4636213 Pakiam Jan 1987 A
4645495 Vaillancourt Feb 1987 A
4653508 Cosman Mar 1987 A
4655765 Swift Apr 1987 A
4657024 Coneys Apr 1987 A
4662652 Hargis May 1987 A
4668221 Luther May 1987 A
4671796 Groshong et al. Jun 1987 A
4673394 Fenton, Jr. et al. Jun 1987 A
4684365 Reinicke Aug 1987 A
4685447 Iversen et al. Aug 1987 A
4685905 Jeanneret nee Aab Aug 1987 A
4692146 Hilger Sep 1987 A
4695273 Brown Sep 1987 A
4697595 Breyer et al. Oct 1987 A
4701166 Groshong et al. Oct 1987 A
4704103 Stöber et al. Nov 1987 A
4710174 Moden et al. Dec 1987 A
4718894 Lazorthes Jan 1988 A
4728894 Yoda et al. Mar 1988 A
4743231 Kay et al. May 1988 A
4753640 Nichols et al. Jun 1988 A
4755173 Konopka et al. Jul 1988 A
4760837 Petit Aug 1988 A
4762517 McIntyre et al. Aug 1988 A
4767410 Moden et al. Aug 1988 A
4772270 Wiita et al. Sep 1988 A
4772276 Wiita et al. Sep 1988 A
4773552 Boege et al. Sep 1988 A
4778452 Moden et al. Oct 1988 A
4781680 Redmond et al. Nov 1988 A
4781685 Lehmann et al. Nov 1988 A
4781695 Dalton Nov 1988 A
4802885 Weeks et al. Feb 1989 A
4804054 Howson et al. Feb 1989 A
4820273 Reinicke Apr 1989 A
4822341 Colone Apr 1989 A
4840615 Hancock et al. Jun 1989 A
4848346 Crawford Jul 1989 A
4857053 Dalton Aug 1989 A
4861341 Woodburn Aug 1989 A
4863470 Carter Sep 1989 A
4886501 Johnston et al. Dec 1989 A
4892518 Cupp et al. Jan 1990 A
4904241 Bark Feb 1990 A
4905709 Bieganski et al. Mar 1990 A
4909250 Smith Mar 1990 A
4915690 Cone et al. Apr 1990 A
4928298 Tanaka et al. May 1990 A
4929236 Sampson May 1990 A
4955861 Enegren et al. Sep 1990 A
4963133 Whipple Oct 1990 A
4966583 Debbas Oct 1990 A
4973319 Melsky Nov 1990 A
4983162 Metais et al. Jan 1991 A
5002735 Alberhasky et al. Mar 1991 A
5009644 McDonald Apr 1991 A
5013298 Moden et al. May 1991 A
5041098 Loiterman et al. Aug 1991 A
5044955 Jagmin Sep 1991 A
5045060 Melsky et al. Sep 1991 A
5045064 Idriss Sep 1991 A
5084015 Moriuchi Jan 1992 A
5085216 Henley, Jr. et al. Feb 1992 A
5090066 Schoepe et al. Feb 1992 A
5092849 Sampson Mar 1992 A
5108317 Beinhaur et al. Apr 1992 A
5108377 Cone et al. Apr 1992 A
5112301 Fenton, Jr. et al. May 1992 A
5112303 Pudenz et al. May 1992 A
5129891 Young Jul 1992 A
5137529 Watson et al. Aug 1992 A
5147483 Melsky et al. Sep 1992 A
5152753 Laguette et al. Oct 1992 A
5156600 Young Oct 1992 A
5158547 Doan et al. Oct 1992 A
5167629 Vertenstein et al. Dec 1992 A
5167633 Mann et al. Dec 1992 A
5167638 Felix et al. Dec 1992 A
5171228 McDonald Dec 1992 A
5176653 Metals et al. Jan 1993 A
5176662 Bartholomew et al. Jan 1993 A
5178612 Fenton, Jr. Jan 1993 A
5185003 Brethauer Feb 1993 A
5189690 Samuel Feb 1993 A
5193106 DeSena Mar 1993 A
5195122 Fabian Mar 1993 A
5195123 Clement Mar 1993 A
5201715 Masters Apr 1993 A
5203771 Melker et al. Apr 1993 A
5203777 Lee Apr 1993 A
5213574 Tucker May 1993 A
5215537 Lynn et al. Jun 1993 A
5222499 Allen et al. Jun 1993 A
D337637 Tucker Jul 1993 S
5224938 Fenton, Jr. Jul 1993 A
5263930 Ensminger Nov 1993 A
5281205 McPherson Jan 1994 A
5290263 Wigness et al. Mar 1994 A
5295658 Atkinson et al. Mar 1994 A
5299253 Wessels Mar 1994 A
5309863 Leeb, Jr. May 1994 A
5312337 Flaherty et al. May 1994 A
5318545 Tucker Jun 1994 A
5320100 Herweck et al. Jun 1994 A
5328480 Melker et al. Jul 1994 A
5332398 Miller et al. Jul 1994 A
5334153 McIntyre et al. Aug 1994 A
5336194 Polaschegg et al. Aug 1994 A
5338398 Szwejkowski et al. Aug 1994 A
5350360 Ensminger et al. Sep 1994 A
5352204 Ensminger Oct 1994 A
5360407 Leonard Nov 1994 A
5383233 Russell Jan 1995 A
5383858 Reilly et al. Jan 1995 A
D355240 Gladfelter et al. Feb 1995 S
5387192 Glantz et al. Feb 1995 A
5394457 Leibinger et al. Feb 1995 A
5395324 Hinrichs et al. Mar 1995 A
5397329 Allen Mar 1995 A
5399168 Wadsworth, Jr. et al. Mar 1995 A
5405402 Dye et al. Apr 1995 A
5417565 Long May 1995 A
5417656 Ensminger et al. May 1995 A
5421814 Geary Jun 1995 A
5423334 Jordan Jun 1995 A
5425762 Muller Jun 1995 A
5433480 Gresham et al. Jul 1995 A
5456698 Byland et al. Oct 1995 A
5476460 Montalvo Dec 1995 A
5476880 Cooke et al. Dec 1995 A
5484402 Saravia et al. Jan 1996 A
5503630 Ensminger et al. Apr 1996 A
5507813 Dowd et al. Apr 1996 A
5509805 Jagmin Apr 1996 A
5513637 Twiss et al. May 1996 A
5514103 Srisathapat et al. May 1996 A
5520632 Leveen et al. May 1996 A
5527277 Ensminger et al. Jun 1996 A
5527307 Srisathapat et al. Jun 1996 A
5531684 Ensminger et al. Jul 1996 A
5556381 Ensminger et al. Sep 1996 A
5558641 Glantz et al. Sep 1996 A
5562617 Finch, Jr. et al. Oct 1996 A
5562618 Cai et al. Oct 1996 A
5575770 Melsky et al. Nov 1996 A
5607393 Ensminger et al. Mar 1997 A
5607407 Tolkoff et al. Mar 1997 A
5613945 Cai et al. Mar 1997 A
5620419 Lui et al. Apr 1997 A
5632729 Cai et al. May 1997 A
5637102 Tolkoff et al. Jun 1997 A
5638832 Singer et al. Jun 1997 A
5647855 Trooskin Jul 1997 A
5662612 Niehoff Sep 1997 A
5676146 Scarborough Oct 1997 A
5695490 Flaherty et al. Dec 1997 A
5702128 Maxim et al. Dec 1997 A
5702363 Flaherty Dec 1997 A
5704915 Melsky et al. Jan 1998 A
5709668 Wacks Jan 1998 A
5713844 Peyman Feb 1998 A
5713858 Heruth et al. Feb 1998 A
5713859 Finch, Jr. et al. Feb 1998 A
5718382 Jaeger Feb 1998 A
5718682 Tucker Feb 1998 A
5725507 Petrick Mar 1998 A
5733336 Neuenfeldt et al. Mar 1998 A
5733400 Gore et al. Mar 1998 A
5741228 Lambrecht et al. Apr 1998 A
5743873 Cai et al. Apr 1998 A
5743891 Tolkoff et al. Apr 1998 A
5746460 Marohl et al. May 1998 A
5758667 Slettenmark Jun 1998 A
5769823 Otto Jun 1998 A
5773552 Hutchings et al. Jun 1998 A
5776188 Shepherd et al. Jul 1998 A
5792104 Speckman et al. Aug 1998 A
5792116 Berg et al. Aug 1998 A
5810789 Powers et al. Sep 1998 A
5824071 Nelson et al. Oct 1998 A
5830172 Leveen et al. Nov 1998 A
5833654 Powers et al. Nov 1998 A
5835563 Navab et al. Nov 1998 A
5836935 Ashton et al. Nov 1998 A
5840063 Flaherty Nov 1998 A
5843069 Butler et al. Dec 1998 A
5853394 Tolkoff et al. Dec 1998 A
5868702 Stevens et al. Feb 1999 A
5882353 VanBeek et al. Mar 1999 A
5895424 Steele, Sr. et al. Apr 1999 A
5906596 Tallarida May 1999 A
5908414 Otto et al. Jun 1999 A
5913998 Butler et al. Jun 1999 A
5916263 Goicoechea et al. Jun 1999 A
5919160 Sanfilippo, II Jul 1999 A
5925017 Kriesel et al. Jul 1999 A
5925030 Gross et al. Jul 1999 A
5928197 Niehoff Jul 1999 A
5931829 Burbank et al. Aug 1999 A
5935084 Southworth Aug 1999 A
5944023 Johnson et al. Aug 1999 A
5944688 Lois Aug 1999 A
5944712 Frassica et al. Aug 1999 A
5947953 Ash et al. Sep 1999 A
5951512 Dalton Sep 1999 A
5951522 Rosato et al. Sep 1999 A
5954687 Baudino Sep 1999 A
5957890 Mann et al. Sep 1999 A
5968011 Larsen et al. Oct 1999 A
5970162 Kawashima et al. Oct 1999 A
5989216 Johnson et al. Nov 1999 A
5989239 Finch et al. Nov 1999 A
5997524 Burbank et al. Dec 1999 A
6007516 Burbank et al. Dec 1999 A
6013051 Nelson Jan 2000 A
6013058 Prosl et al. Jan 2000 A
6017331 Watts et al. Jan 2000 A
6022335 Ramadan Feb 2000 A
6033389 Cornish Mar 2000 A
6039712 Fogarty et al. Mar 2000 A
6077756 Lin et al. Jun 2000 A
6086555 Eliasen Jul 2000 A
6090066 Schnell Jul 2000 A
6102884 Squitieri Aug 2000 A
6113572 Gailey et al. Sep 2000 A
6120492 Finch et al. Sep 2000 A
6161033 Kuhn Dec 2000 A
6171198 Lizama Troncoso et al. Jan 2001 B1
6171298 Matsuura et al. Jan 2001 B1
6174330 Stinson Jan 2001 B1
6190352 Haarala et al. Feb 2001 B1
6193684 Burbank et al. Feb 2001 B1
6198807 DeSena Mar 2001 B1
6203570 Baeke Mar 2001 B1
6213973 Eliasen et al. Apr 2001 B1
6228088 Miller et al. May 2001 B1
6251059 Apple et al. Jun 2001 B1
D445175 Bertheas Jul 2001 S
6269148 Jessop et al. Jul 2001 B1
6287293 Jones et al. Sep 2001 B1
6290677 Arai et al. Sep 2001 B1
6302875 Makower et al. Oct 2001 B1
6305413 Fischer et al. Oct 2001 B1
D450115 Bertheas Nov 2001 S
6332874 Eliasen et al. Dec 2001 B1
6347241 Burbank et al. Feb 2002 B2
6355021 Nielsen et al. Mar 2002 B1
6356782 Sirimanne et al. Mar 2002 B1
6361557 Gittings et al. Mar 2002 B1
6398764 Finch, Jr. et al. Jun 2002 B1
6419680 Cosman et al. Jul 2002 B1
6450937 Mercereau et al. Sep 2002 B1
6478783 Moorehead Nov 2002 B1
6482217 Pintor et al. Nov 2002 B1
6494867 Elver et al. Dec 2002 B1
6497062 Koopman et al. Dec 2002 B1
6500155 Sasso Dec 2002 B2
6503228 Li et al. Jan 2003 B1
6527754 Tallarida et al. Mar 2003 B1
6537255 Raines Mar 2003 B1
RE38074 Recinella et al. Apr 2003 E
6582418 Verbeek et al. Jun 2003 B1
6613002 Clark et al. Sep 2003 B1
6613662 Wark et al. Sep 2003 B2
6626936 Stinson Sep 2003 B2
6629950 Levin Oct 2003 B1
6632217 Harper et al. Oct 2003 B2
6652486 Bialecki et al. Nov 2003 B2
6652503 Bradley Nov 2003 B1
6676633 Smith et al. Jan 2004 B2
6697664 Kienzle, III et al. Feb 2004 B2
6705316 Blythe et al. Mar 2004 B2
6719721 Okazaki et al. Apr 2004 B1
6719739 Verbeek et al. Apr 2004 B2
6738531 Funahashi May 2004 B1
6755842 Kanner et al. Jun 2004 B2
6758841 Haarala et al. Jul 2004 B2
6767356 Kanner et al. Jul 2004 B2
6784783 Scoggin et al. Aug 2004 B2
6826257 Sayre et al. Nov 2004 B2
6852106 Watson et al. Feb 2005 B2
6878136 Fleury et al. Apr 2005 B2
6878137 Benchetrit Apr 2005 B2
6949084 Marggi et al. Sep 2005 B2
6962580 Adams et al. Nov 2005 B2
6994315 Ryan et al. Feb 2006 B2
6997914 Smith et al. Feb 2006 B2
7008377 Beane et al. Mar 2006 B2
7008412 Maginot Mar 2006 B2
7016456 Basu et al. Mar 2006 B2
7018361 Gillespie, Jr. et al. Mar 2006 B2
7044942 Jolly et al. May 2006 B2
7056316 Burbank et al. Jun 2006 B1
7070591 Adams et al. Jul 2006 B2
7072704 Bucholz Jul 2006 B2
7074232 Kanner et al. Jul 2006 B2
7076305 Imran et al. Jul 2006 B2
7083593 Stultz Aug 2006 B2
7108686 Burke et al. Sep 2006 B2
7123690 Brown et al. Oct 2006 B1
7127040 Sayre et al. Oct 2006 B2
7131962 Estabrook et al. Nov 2006 B1
7140769 Kay Nov 2006 B2
7191011 Cantlon Mar 2007 B2
7198631 Kanner et al. Apr 2007 B2
7214207 Lynch et al. May 2007 B2
7214215 Heinzerling et al. May 2007 B2
7223257 Shubayev et al. May 2007 B2
7229417 Foerster et al. Jun 2007 B2
7235067 Morris et al. Jun 2007 B2
D546440 Burnside Jul 2007 S
7242982 Singhal et al. Jul 2007 B2
7252469 Zaluzec et al. Aug 2007 B2
7252649 Sherry Aug 2007 B2
7261705 Edoga et al. Aug 2007 B2
D554253 Kornerup Oct 2007 S
7275682 Excoffier et al. Oct 2007 B2
7276075 Callas et al. Oct 2007 B1
D556153 Burnside Nov 2007 S
7306579 Fujii Dec 2007 B2
7311702 Tallarida et al. Dec 2007 B2
7318816 Bobroff et al. Jan 2008 B2
7318818 Yashiro et al. Jan 2008 B2
7322953 Redinger Jan 2008 B2
D562443 Zinn et al. Feb 2008 S
7331130 Schweikert Feb 2008 B2
7331948 Skarda Feb 2008 B2
7333013 Berger Feb 2008 B2
D564449 Dewberry Mar 2008 S
7347838 Kulli Mar 2008 B2
7347843 Adams et al. Mar 2008 B2
7351233 Parks Apr 2008 B2
7377915 Rasmussen et al. May 2008 B2
D574950 Zawacki et al. Aug 2008 S
7413564 Morris et al. Aug 2008 B2
D578203 Bizup Oct 2008 S
7445614 Bunodiere et al. Nov 2008 B2
D582032 Bizup et al. Dec 2008 S
7465847 Fabian Dec 2008 B2
D595892 Smith et al. Jul 2009 S
7563025 Kay Jul 2009 B2
7648517 Makower et al. Jan 2010 B2
7713251 Tallarida et al. May 2010 B2
7833281 Lehman et al. Nov 2010 B2
20010016717 Haarala et al. Aug 2001 A1
20010051766 Gazdzinski Dec 2001 A1
20010053889 Marggi et al. Dec 2001 A1
20010056266 Tallarida et al. Dec 2001 A1
20020095205 Edwin et al. Jul 2002 A1
20020138068 Watson et al. Sep 2002 A1
20020173769 Gray et al. Nov 2002 A1
20030010929 Priewe et al. Jan 2003 A1
20030028173 Forsberg Feb 2003 A1
20030130627 Smith et al. Jul 2003 A1
20030139812 Garcia et al. Jul 2003 A1
20030181878 Tallarida et al. Sep 2003 A1
20030191452 Meglin et al. Oct 2003 A1
20040002693 Bright et al. Jan 2004 A1
20040006316 Patton Jan 2004 A1
20040019356 Fraser et al. Jan 2004 A1
20040020462 Sauler et al. Feb 2004 A1
20040044306 Lynch et al. Mar 2004 A1
20040054352 Adams et al. Mar 2004 A1
20040056266 Suh et al. Mar 2004 A1
20040064110 Forsell Apr 2004 A1
20040073196 Adams et al. Apr 2004 A1
20040093069 Priewe et al. May 2004 A1
20040106878 Skujins et al. Jun 2004 A1
20040106891 Langan et al. Jun 2004 A1
20040157952 Soffiati et al. Aug 2004 A1
20040158207 Hunn et al. Aug 2004 A1
20040167543 Mazzocchi et al. Aug 2004 A1
20040176743 Morris et al. Sep 2004 A1
20040199129 DiMatteo Oct 2004 A1
20040199220 Cantlon Oct 2004 A1
20040204692 Eliasen Oct 2004 A1
20040225254 Tanaka et al. Nov 2004 A1
20040254536 Conlon et al. Dec 2004 A1
20040254537 Conlon et al. Dec 2004 A1
20050049553 Triplett et al. Mar 2005 A1
20050070875 Kulessa Mar 2005 A1
20050075614 Bunodiere et al. Apr 2005 A1
20050113806 De Carvalho et al. May 2005 A1
20050131352 Conlon et al. Jun 2005 A1
20050148866 Gunderson Jul 2005 A1
20050148956 Conlon et al. Jul 2005 A1
20050148957 Girard et al. Jul 2005 A1
20050152841 Sayre et al. Jul 2005 A1
20050171502 Daly et al. Aug 2005 A1
20050182857 Kong Aug 2005 A1
20050209573 Brugger et al. Sep 2005 A1
20050215874 Wang et al. Sep 2005 A1
20050215876 Chen et al. Sep 2005 A1
20050241203 Lizotte et al. Nov 2005 A1
20050256451 Adams et al. Nov 2005 A1
20050256500 Fujii Nov 2005 A1
20050277899 Conlon et al. Dec 2005 A1
20050283119 Uth et al. Dec 2005 A1
20060009788 Freeman et al. Jan 2006 A1
20060017341 Hahn et al. Jan 2006 A1
20060084929 Eliasen Apr 2006 A1
20060089619 Ginggen Apr 2006 A1
20060100592 Eliasen May 2006 A1
20060116648 Hamatake Jun 2006 A1
20060173410 Moberg et al. Aug 2006 A1
20060173424 Conlon Aug 2006 A1
20060178647 Stats Aug 2006 A1
20060184141 Smith et al. Aug 2006 A1
20060184142 Schon et al. Aug 2006 A1
20060217359 Wentworth et al. Sep 2006 A1
20060217659 Patton Sep 2006 A1
20060224128 Lurvey et al. Oct 2006 A1
20060247584 Sheetz et al. Nov 2006 A1
20060253076 Butts et al. Nov 2006 A1
20060264898 Beasley et al. Nov 2006 A1
20070007839 Lin Jan 2007 A1
20070049876 Patton Mar 2007 A1
20070055290 Lober Mar 2007 A1
20070073250 Schneiter Mar 2007 A1
20070078391 Wortley et al. Apr 2007 A1
20070078416 Eliasen Apr 2007 A1
20070078432 Halseth et al. Apr 2007 A1
20070083156 Muto et al. Apr 2007 A1
20070149920 Michels et al. Jun 2007 A1
20070149921 Michels et al. Jun 2007 A1
20070161958 Glenn Jul 2007 A1
20070161985 Demakas et al. Jul 2007 A1
20070179456 Glenn Aug 2007 A1
20070185462 Byrum Aug 2007 A1
20070191773 Wojcik Aug 2007 A1
20070208313 Conlon et al. Sep 2007 A1
20070219510 Zinn et al. Sep 2007 A1
20070233017 Zinn et al. Oct 2007 A1
20070233018 Bizup et al. Oct 2007 A1
20070255234 Haase et al. Nov 2007 A1
20070270691 Bailey et al. Nov 2007 A1
20070270770 Bizup Nov 2007 A1
20070276344 Bizup et al. Nov 2007 A1
20070299408 Alferness et al. Dec 2007 A1
20080004642 Birk et al. Jan 2008 A1
20080008654 Clarke et al. Jan 2008 A1
20080015701 Garcia et al. Jan 2008 A1
20080039820 Sommers et al. Feb 2008 A1
20080048855 Berger Feb 2008 A1
20080108949 Beasley et al. May 2008 A1
20080114308 di Palma et al. May 2008 A1
20080138387 Machiraju Jun 2008 A1
20080140025 Sheetz et al. Jun 2008 A1
20080208236 Hobbs et al. Aug 2008 A1
20080281279 Hoendervoogt et al. Nov 2008 A1
20080319398 Bizup Dec 2008 A1
20080319399 Schweikert et al. Dec 2008 A1
20080319405 Bizup Dec 2008 A1
20090024024 Zinn Jan 2009 A1
20090024098 Bizup et al. Jan 2009 A1
20090035582 Nakatani et al. Feb 2009 A1
20090118683 Hanson et al. May 2009 A1
20090156928 Evans et al. Jun 2009 A1
20090171436 Casanova et al. Jul 2009 A1
20090204072 Amin et al. Aug 2009 A1
20090204074 Powers et al. Aug 2009 A1
20090221976 Linden Sep 2009 A1
20090227862 Smith et al. Sep 2009 A1
20090227951 Powers et al. Sep 2009 A1
20100004735 Yang et al. Jan 2010 A1
20100042073 Oster et al. Feb 2010 A1
20100069743 Sheetz et al. Mar 2010 A1
Foreign Referenced Citations (58)
Number Date Country
84 37 873 Feb 1986 DE
34 47 202 Jul 1986 DE
197 45 654 Apr 1999 DE
0619101 Oct 1994 EP
0 750 520 Aug 2000 EP
1 238 682 Sep 2002 EP
2 569 987 Mar 1986 FR
2 586 569 Mar 1987 FR
2 203 342 Oct 1988 GB
2500388 Jun 1996 JP
08-168322 Jul 1996 JP
2602109 Apr 1997 JP
2003-102831 Apr 2003 JP
2004-350937 Dec 2004 JP
2006-025948 Feb 2006 JP
WO 8600213 Jan 1986 WO
WO 9305730 Apr 1993 WO
9514504 Jun 1995 WO
WO 9701370 Jan 1997 WO
9706845 Feb 1997 WO
9711726 Apr 1997 WO
WO 9817337 Apr 1998 WO
WO 9942166 Aug 1999 WO
WO 0033901 Jun 2000 WO
0047264 Aug 2000 WO
WO 0247549 Jun 2002 WO
02100480 Dec 2002 WO
03037215 May 2003 WO
03086508 Oct 2003 WO
WO 2004004800 Jan 2004 WO
WO 2004071555 Aug 2004 WO
WO 2005037055 Apr 2005 WO
WO 2004091434 Oct 2005 WO
WO 2006078915 Jul 2006 WO
WO 2006096686 Sep 2006 WO
WO 2006116438 Nov 2006 WO
WO 2006130133 Dec 2006 WO
WO 2006134100 Dec 2006 WO
WO 2007079024 Jul 2007 WO
WO 2007092210 Aug 2007 WO
WO 2007094898 Aug 2007 WO
WO 2007098771 Sep 2007 WO
WO 2007109164 Sep 2007 WO
WO 2007126645 Nov 2007 WO
WO 2007136538 Nov 2007 WO
WO 2008008126 Jan 2008 WO
WO 2008019236 Feb 2008 WO
WO 2008048361 Apr 2008 WO
WO 2008063226 May 2008 WO
WO 2008147760 Dec 2008 WO
WO 2009002839 Dec 2008 WO
WO 2008157763 Dec 2008 WO
WO 2009012385 Jan 2009 WO
WO 2009012395 Jan 2009 WO
WO 2009035582 Mar 2009 WO
WO 2009046725 Apr 2009 WO
WO 2009046439 Apr 2009 WO
WO 2009108669 Sep 2009 WO
Non-Patent Literature Citations (159)
Entry
U.S. Appl. No. 12/175,270, Response, filed Apr. 5, 2011, 7 pages.
U.S. Appl. No. 12/175,270, Office Action, dated May 26, 2011, 6 pages.
U.S. Appl. No. 12/175,270, Response, filed Aug. 22, 2011, 18 pages.
U.S. Appl. No. 12/175,270, Office Action, dated Sep. 14, 2011, 6 pages.
U.S. Appl. No. 11/725,287, Supplemental Response and Suggestion of Interference, filed May 26, 2011, 62 pages.
U.S. Appl. No. 11/725,287, Office Action, mailed Oct. 5, 2011, 6 pages.
U.S. Appl. No. 12/143,377, Office Action, dated Feb. 4, 2010, 15 pages.
U.S. Appl. No. 12/143,377, Office Action, dated Sep. 13, 2010, 17 pages.
U.S. Appl. No. 12/143,377, Response, dated Aug. 27, 2009, 7 pages.
U.S. Appl. No. 12/143,377, Response, filed Jan. 13, 2011, 17 pages.
U.S. Appl. No. 12/143,377, Response, filed Jan. 19, 2010, 15 pages.
U.S. Appl. No. 12/143,377, Response, filed Jul. 6, 2010, 14 pages.
U.S. Appl. No. 12/143,377, Office Action, dated Apr. 27, 2009, 6 pages.
U.S. Appl. No. 12/143,377, Office Action, dated Oct. 19, 2009, 9 pages.
BARD Access System product drawings representative of the BARD Access System products on the market on or around Mar. 1995 as indicated by the BARD Access Systems Mar. 21, 1995 Product Release to Market form for “M.R.I. Port with 8 Fr. ChronoFlex® Catheter,” “M.R.I. Port with 8 Fr. ChronoFlex Catheter with Intro-Eze™,” “M.R.I. Port with 8 Fr. Chrono-Flex Catheter and Peel Apart,” “M.R.I. Port with 8 Fr. ChronoFlex Catheter Demo Kit,” 6 pages.
BioEnterics® LAP-BAND® “Adjustable Gastric Banding System” by Inamed Health, Product Brochure, Dec. 2003, 22 pages.
Cardiovascular and Interventional Radiology, Review Article, “Central Venous Access Catheters: Radiological Management of Complications,” by U.K. Teichgraber et al., published online Jul. 31, 2003, 13 pages.
European Patent Office Communication, dated Dec. 15, 2005, for Application No. 99 964 086.5-1257, Applicant STD Manufacturing, Inc., 9 pages.
European Patent Office Communication, dated Mar. 1, 2005, for EP Application No. 99 964 086.5-1257, Applicant STD Manufacturing, Inc., 4 pages.
European Patent Office Communication, dated Mar. 30, 2005, for Application No. 99 964 086.5-1257, Applicant STD Manufacturing, Inc., 3 pages.
European Patent Office Communication, dated Sep. 2, 2008, for Application No. 06 751 411.7-1526, Applicant C.R. Bard, Inc., 4 pages.
LaMaitre Vascular “Port Implantations: using the OptiLock Implantable Port,” product information, available at http://www.lemaitre. com/specs—pop.asp, last accessed Apr. 2003, 14 pages.
LAP-BAND AP™ “System with Adjustable Gastric Banding system with OMNIFORM™ Design,” Product Brochure, Jul. 2007, 16 pages.
LAP-BAND® “Adjustable Gastric Banding System” by BioEnterics Corporation, Product Brochure, 12 pages.
LAP-BAND® System Fact Sheet, © 2007 Allergan, Inc., 2 pages.
MedComp “PortCT Technology”, display at SIR Conference, Toronto, Canada, (Mar. 2006), 1 page.
Nucleus Cochlear Implant Systems; User Manual for the ESPrit 3G speech processor and accessories, available at http://www.cochlearamericas.com/PDFs/UserManualSprint.pdf, Issue 2, Dec. 2001, 2 pages.
Oct. 22, 2009 Declaration of Kelly Christian, Director of Product Development at BARD Access Systems, Inc, in support of and depicting a product on the market by Quinton Company approximately ten years prior to Oct. 22, 2009, 1 page.
PORT-A-CATH® “Implantable Epidural, Aterial and Peritonial Access Systems,” Internet Product Listing of Nov. 19, 2000 archived at http://web. archive.org/web/20001119035900/www.deltec.com/cPacspl.htm, last accessed Oct. 17, 2009, 2 pages.
PORT-A-CATH® “Many PORT-A-CATH® System Choices,” Product Brochure, © 1996 SIMS Deltec, Inc., 5 pages.
PORT-A-CATH® “Single-lumen Implantable Vascular Access Systems,” Product Specifications, 2004 Smith Medical, 4 pages.
Rappolt, Richard T., et al., “Radiopaque Codification and X-ray identification of Ingested Drugs,” Ingestive Radioiogy, May-Jun. 1966, 4 pages.
Shah, Tilak M. “Radiopaque Polymer Formulations for Medical Devices.” Medical Device and Diagnostic Industry, Mar. 2000, 6 pages.
Urquiola, Javier, et al., “Using Lead Foil as a Radiopaque Marker for Computerized Tomography Imaging When Implant Treatment Planning,” The Journal of Prosthetic Dentistry, vol. 77, No. 2, Feb. 1997, pp. 227-228.
PCT/US06/008022 International Search Report, mailed Jul. 5, 2006, 2 pages.
PCT/US06/015695 International Search Report, mailed Jan. 11, 2007, 6 pages.
PCT/US06/49007 International Search Report, mailed Oct. 1, 2007, 2 pages.
PCT/US06/49007 Written Opinion, mailed Oct. 1, 2007, 4 pages.
PCT/US07/006776 International Search Report, mailed Dec. 18, 2007, 1 page.
PCT/US07/006776 Written Opinion, mailed Dec. 18, 2007, 3 pages.
PCT/US08/067679 International Search Report, mailed Sep. 30, 2008, 3 pages.
PCT/US08/067679 Written Opinion, mailed Sep. 30, 2008, 4 pages.
PCT/US08/070330 International Search Report, mailed Dec. 1, 2008, 5 pages.
PCT/US08/070330 Written Opinion, mailed Dec. 1, 2008, 5 pages.
PCT/US08/070345 International Search Report, mailed Dec. 1, 2008, 5 pages.
PCT/US08/070345 Written Opinion, mailed Dec. 1, 2008, 6 pages.
U.S. Appl. No. 10/374,000, Advisory Action, mailed Jan. 23, 2007, 3 pages.
U.S. Appl. No. 10/374,000, Office Action, mailed Aug. 28, 2007, 8 pages.
U.S. Appl. No. 10/374,000, Office Action, mailed Feb. 13, 2006, 7 pages.
U.S. Appl. No. 10/374,000, Office Action, mailed Feb. 28, 2007, 8 pages.
U.S. Appl. No. 10/374,000, Office Action, mailed Jul. 28, 2006, 8 pages.
U.S. Appl. No. 10/374,000, Office Action, mailed Mar. 20, 2008, 6 pages.
U.S. Appl. No. 10/374,000, Office Action, mailed May 20, 2009, 9 pages.
U.S. Appl. No. 10/374,000, Office Action, mailed Sep. 30, 2008, 7 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Dec. 28, 2006, 9 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Jun. 20, 2008, 8 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Mar. 30, 2009, 11 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed May 12, 2006, 7 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed May 29, 2007, 2006, 11 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Oct. 31, 2007, 8 pages.
U.S. Appl. No. 10/374,000, Response to Office Action, filed Sep. 21, 2009, 13 pages.
U.S. Appl. No. 11/320,223, Office Action, mailed Feb. 13, 2008, 11 pages.
U.S. Appl. No. 11/320,223, Office Action, mailed Sep. 18, 2008, 7 pages.
U.S. Appl. No. 11/368,954, Preliminary Amendment, filed Dec. 19, 2007, 9 pages.
U.S. Appl. No. 11/380,124, Office Action, mailed Jan. 16, 2009, 10 pages.
U.S. Appl. No. 11/725,287, Office Action, mailed Jun. 12, 2009, 5 pages.
U.S. Appl. No. 11/725,287, Office Action, mailed Dec. 3, 2008, 7 pages.
U.S. Appl. No. 12/175,182, Office Action, mailed Sep. 3, 2009, 7 pages.
U.S. Appl. No. 29/284,454, filed Sep. 7, 2007, entitled “Implantable Port Device,” issued Aug. 12, 2008 as U.S. Patent No. D574,950, 8 pages.
U.S. Appl. No. 29/284,456, filed Sep. 7, 2007 entitled “Implantable Port Device,” 8 pages.
U.S. Appl. No. 60/658,518, filed Mar. 4, 2005, publicly accessible Oct. 5, 2006, 62 pages.
Plinski, et al., “Implantable Cardioverter-Defibrillators: Implications for the Nonelectrophysiologist.” Annals of Internal Medicine, Abstract of vol. 122 No. 10, pp. 770-777, May 15, 1995, 3 pages.
Thistlethwaite et al., “Generalized Feature-Based RSA of Orthopaedic Implants.” 2003 Summer Bioengineering Conference, Jun. 25-29, Sonesta Beach Resort in Key Biscayne, Florida, 2 pages.
U.S. Appl. No. 11/725,287, Response, mailed Oct. 11, 2011, 5 pages.
U.S. Appl. No. 11/725,287, Declaration of Interference, mailed Nov. 10, 2011, 6 pages.
U.S. Appl. No. 12/175,270, Response, filed Jan. 17, 2012, 10 pages.
“Extravasation of Radiologic Contrast.” PA-PSRS Patient Safety Advisory—vol. 1, No. 3, Sep. 2004, 6 pages.
Biffi, R. et al. “Best Choice of Central Venous Insertion Site for the Prevention of Catheter-Related Complications in Adult Patients Who Need Cancer Therapy: A Randomized Trial.” Annals of Oncology, Jan. 29, 2009, 6 pages.
Biffi, R. et al. “Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients.” Annals of Oncology 15:296-300, 2004, 5 pages.
Biffi, Roberto, et al. “A Randomized, Prospective Trial of Central Venous Ports Connected to Standard Open-Ended or Groshong Catheters in Adult Oncology Patients.” American Cancer Society, vol. 92, No. 5, pp. 1204-1212, Sep. 1, 2001, 9 pages.
Costa, Nancy, “More Than Skin Deep: An Overview of Iodinated Contrast Media.” Journal for the Association for Vascular Access, vol. 8, No. 4, 2003, 6 pages.
Costa, Nancy, “Understanding Contrast Media.” Journal of Infusion Nursing, vol. 27, No. 5, Sep./Oct. 2004, 11 pages.
Extreme Access, Bard Access Systems, Inc., Product Brochure, 2003, 5 pages.
Fallscheer, et al., “Injury to the Upper Extremity Caused by Extravasation of Contrast Medium: A True Emergency.” Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, vol. 41, pp. 26-32, 2007, 7 pages.
Hou, Shaw-Min et al. “Comparisons of Outcomes and Survivals for Two Central Venous Access Port Systems.” Journal of Surgical Oncology, 91:61-66, 2005, 6 pages.
Johnson, Kathleen A., “Power Injectable Portal Systems,” Journal of Radiology Nursing, vol. 28, Issue 1, Mar. 2009, 6 pages.
LAP-BAND System Access Port Fill Guide I, “9.75/10.0 cm LAP-BAND System vs. 11 cm LAP-BAND System: For Product Manufactured Prior to Jul. 2001” BioEnterics Corporation, 1 page.
Port-A-Cath P.A.S. PORT Systems by Deltec, Product Specifications, 1999, 2 pages.
Sandstede, Joern, “Pediatric CT,” available online at www.multislice-ct.com, MultiSLICE-CT.com, version 02, May 2, 2003, 36 pages.
Sanelli, et al., “Safety and Feasibility of Using a Central Venous Catheter for Rapid Contrast Injection Rates.” American Journal of Radiology, vol. 183, pp. 1829-1834, Dec. 2004, 6 pages.
Smith, Lisa Hartkoph, “Implanted Ports, Computer Tomography, Power Injectors, and Catheter Rupture.” Clinical Journal of Oncology Nursing, vol. 12, No. 5 Oct. 2008, 4 pages.
Solomon, et al., “CIN Strategies: Anticipate, Manage, Prevent.” Supplement to Imaging Economics, May 2007, 20 pages.
Steinbach, Barbara, G., Hardt, N. Sisson, Abbitt, Patricia L., Lanier, Linda, Caffee, H. Hollis, “Breast Implants, Common Complications, and Concurrent Breast Disease.” RadioGraphics, vol. 13, No. 1, pp. 95-118, 1993, 24 pages.
Sullivan et al. “Radiopaque Markers on Mammary Implants.” American Journal of Roentgenology 153(2):428, Aug. 1989, 2 pages.
U.S. Food and Drug Administration, “Guidance for Institutional Review Boards and Clinical Investigators 1998 Update: Medical Devices.” Version Sep. 10, 2008, 13 pages.
Vergara, et al., “Adverse Reactions to Contrast Media in CT: Effects of Temperature and Ionic Property.” Radiology, vol. 199, No. 2, May 1996, 4 pages.
Vogelzang, Robert L., “Power Injection Through Central Venous Catheters: Physiological and Hemodynamic Considerations.” The McGaw Medical Center of Northwestern University, Feinberg School of Medicine, 3 pages.
Wells, S. “Venous Access in Oncology and Haematology Patients: Part One.” Nursing Standard, vol. 22, No. 52, pp. 39-46, Sep. 3, 2008, 9 pages.
Williamson, et al., “Assessing the Adequacy of Peripherally Inserted Central Catheters for Power Injection of Intravenous Contrast Agents for CT.” Journal of Computer Assisted Tomography, vol. 6, No. 6, pp. 932-937, 2001, 6 pages.
International Application No. PCT/US1999/028695, International Preliminary Examination Report, dated Apr. 21, 2001, 4 pages.
International Application No. PCT/US1999/028695, International Search Report, dated Apr. 11, 2000, 2 pages.
International Application No. PCT/US2006/008022, International Preliminary Report on Patentability and Written Opinion, dated Sep. 12, 2007, 6 pages.
International Application No. PCT/US2006/015695, International Preliminary Report on Patentability and Written Opinion, dated Oct. 30, 2007, 9 pages.
International Application No. PCT/US2006/016056, International Preliminary Report on Patentability and Written Opinion, dated Oct. 30, 2007, 9 pages.
International Application No. PCT/US2006/016056, International Search Report, dated Sep. 20, 2006, 4 pages.
International Application No. PCT/US2006/049007, International Preliminary Report on Patentability and Written Opinion, dated Jul. 1, 2008, 5 pages.
International Application No. PCT/US2007/006776, International Preliminary Report on Patentability, dated Mar. 6, 2008, 3 pages.
International Application No. PCT/US2007/011015, International Preliminary Report on Patentability, dated Nov. 23, 2009, 9 pages.
International Application No. PCT/US2007/011015, International Search Report, dated Jun. 10, 2008, 2 pages.
International Application No. PCT/US2007/011015, Written Opinion, dated Jun. 10, 2008, 3 pages.
International Application No. PCT/US2007/011456, International Search Report, dated Aug. 28, 2008, 2 pages.
International Application No. PCT/US2007/011456, Written Opinion, dated Aug. 28, 2008, 4 pages.
International Application No. PCT/US2008/010520, International Search Report, dated Feb. 24, 2009, 2 pages.
International Application No. PCT/US2008/010520, Written Opinion, dated Feb. 24, 2009, 4 pages.
International Application No. PCT/US2008/078976, International Search Report and Written Opinion, dated Apr. 3, 2009, 6 pages.
International Application No. PCT/US2009/062854, International Search Report, dated Dec. 23, 2009, 2 pages.
U.S. Appl. No. 11/320,223, Office Action, mailed Jan. 21, 2010, 8 pages.
U.S. Appl. No. 11/368,954, Interview Summary Communication from the USPTO, mailed May 12, 2010, 3 pages.
U.S. Appl. No. 11/368,954, Office Action, mailed Jan. 27, 2010, 7 pages.
U.S. Appl. No. 11/380,124, Office Action, dated Apr. 26, 2010, 7 pages.
U.S. Appl. No. 11/380,124, Office Action, dated Sep. 21, 2009, 8 pages.
U.S. Appl. No. 11/380,621, Office Action, dated Jan. 14, 2010, 17 pages.
U.S. Appl. No. 11/380,621, Office Action, dated Jul. 1, 2009, 16 pages.
U.S. Appl. No. 11/380,621, Office Action, dated Jun. 6, 2008, 16 pages.
U.S. Appl. No. 11/725,287, Notice of Allowance, dated Aug. 29, 2009, 4 pages.
U.S. Appl. No. 11/725,287, Notice of Withdrawal from Issue, dated Oct. 23, 2009, 1 page.
U.S. Appl. No. 11/725,287, Office Action, dated Mar. 29, 2010.
U.S. Appl. No. 11/725,287, Response, filed Feb. 24, 2009, 9 pages.
U.S. Appl. No. 11/725,287, Response, filed Jul. 28, 2009, 4 pages.
U.S. Appl. No. 11/725,287, Response, filed Sep. 29, 2010, 10 pages.
U.S. Appl. No. 12/023,280, Office Action, dated Jul. 23, 2009, 11 pages.
U.S. Appl. No. 12/023,280, Office Action, dated Oct. 5, 2009, 9 pages.
U.S. Appl. No. 12/175,182, Office Action, dated Feb. 22, 2010, 6 pages.
U.S. Appl. No. 12/175,182, Office Action, dated Jul. 22, 2010, 7 pages.
U.S. Appl. No. 12/175,182, Response, filed Dec. 3, 2009, 13 pages.
U.S. Appl. No. 12/175,182, Response, filed Jun. 22, 2010, 14 pages.
U.S. Appl. No. 12/175,182, Response, filed Jan. 24, 2011, 13 pages.
U.S. Appl. No. 12/175,182, Notice of Allowability, mailed Mar. 9, 2011, 5 pages.
U.S. Appl. No. 12/175,270, Office Action, dated Jan. 5, 2011, 6 pages.
U.S. Appl. No. 12/419,957, Office Action, dated Jun. 30, 2009, 6 pages.
U.S. Appl. No. 12/419,957, Office Action, mailed Feb. 18, 2010, 6 pages.
U.S. Appl. No. 12/420,007, Office Action, dated Feb. 18, 2010, 9 pages.
U.S. Appl. No. 12/420,007, Office Action, dated Jul. 14, 2009, 7 pages.
U.S. Appl. No. 29/247,954, Notice of Allowability, dated Jul. 30, 2007, 3 pages.
U.S. Appl. No. 29/247,954, Office Action, dated Apr. 6, 2007, 6 pages.
U.S. Appl. No. 11/725,287, Office Action, dated Dec. 7, 2011, 4 pages.
U.S. Appl. No. 11/725,287, Response, filed Jan. 6, 2011, 10 pages.
U.S. Appl. No. 11/725,287, Supplemental Response and Suggestion of Interference, filed Feb. 18, 2011, 64 pages.
Medtronic, Inc., “Iso-Med Constant-Flow Infusion System” Publication, Sep. 2000, 111 pages.
Reexamination Control No. 95/002,092, Request for Inter Partes Reexamination of U.S. Patent No. 7,959,615, dated Aug. 20, 2012, 158 pages.
Reexamination Control No. 95/002,092, Order granting Inter Partes Reexamination, dated Nov. 13, 2012, 19 pages.
Reexamination Control No. 95/002,092, Office Action, dated Nov. 13, 2012, 12 pages.
Reexamination Control No. 95/002,090, Request for Inter Partes Reexamination of U.S. Patent No. 7,947,022, dated Aug. 20, 2012, 181 pages.
Reexamination Control No. 95/002,090, Order granting Inter Partes Reexamination, dated Nov. 7, 2012, 15 pages.
Reexamination Control No. 95/002,090, Office Action, dated Nov. 7, 2012, 17 pages.
Reexamination Control No. 95/002,089, Request for Inter Partes Reexamination of U.S. Patent No. 7,785,302, dated Aug. 20, 2012, 189 pages.
Reexamination Control No. 95/002,089, Order granting Inter Partes Reexamination, dated Nov. 7, 2012, 19 pages.
Reexamination Control No. 95/002,089, Office Action, dated Nov. 7, 2012, 16 pages.
U.S. Appl. No. 12/143,377, Notice of Allowance, mailed Jul. 5, 2012, 8 pages.
Related Publications (1)
Number Date Country
20120283560 A1 Nov 2012 US
Provisional Applications (1)
Number Date Country
60936491 Jun 2007 US
Continuations (1)
Number Date Country
Parent 12143377 Jun 2008 US
Child 13549998 US